Abstract

No abstract

No abstract

Programs are demarcated as administrative structures established to realize planned organizational strategies through multi-project activities. Programs occupy a distinct locus in organizational hierarchy, so therefore necessitate specialized management approaches. Risks in programs tend to widen the gap between the organizational plans and the actual program realizations. However, effective risk management can minimize these gaps. This research frames a structured approach for program risk management, called Risk Leveling in Program Environments (RLPE), which suggests (a) a deliberate shift of risks to the right organizational level where they can be addressed most effectively; and (b) a unique procedure for risk management, which attempts to stabilize the risky contexts in programs. RLPE tracks the standard risk management process, preserves distinct program locus, and employs certain qualitative and quantitative measures to achieve risk leveled environments for program success. It has been demonstrated how certain tools and concepts, such as Analytical Hierarchy Process (AHP), As Low As Reasonably Practicable (ALARP), standard deviation, etc. can be employed for risk oriented decision making in programs. RLPE is an instrumental approach, which can help the policy makers in controlling the risky contexts thereby providing sustainable growth for development programs. The offered approach can be particularly advantageous for risk management in large-scale (development) programs. OPEN ACCESSSustainability 2015, 7 5897

The aim of this study is to develop (177) Lu-5-Flourouracil as a potential cancer therapeutic radiopharmaceutical. 5-Flourouracil (5-FU) is widely accepted as an anticancer drug of broad spectrum fame. The labeling of 5-FU was carried out at different set of experimental conditions using high specific activity of (177) LuCl3 . The optimum conditions for maximum radiochemical yield was set: 5-FU (5 mg), (177) LuCl3 (185 MBq), diethylenetriaminepentaacetic acid (10 µg), reaction volume (2 mL), pH (5.5), temperature (80°C), and reaction time (20 min). The radiochemical labeling was assessed with Whatman No. 2 paper, instant thin layer chromatographic, and radio-HPLC, which revealed >94% labeling results with sufficient stability up to 6 h. Serum stability study also showed (177) Lu-5-FU promising stability. Biodistribution study in normal rats and rabbits showed liver, stomach, kidney, and heart as area of increased tracer accumulation just after injection, which decreased to 1.4%, 0.4%, 0.2%, and 0.39% ID/g, respectively, after 72 h. Glomerular filtration rate and cytotoxicity study results of (177) Lu-5-FU showed it had no adverse effect on renal function and nontoxic to blood cells. The promising characteristics of (177) Lu-5-FU, that is, clever elimination from kidney and nontoxic nature toward blood cells make it the radiopharmaceutical for further testing in patients for therapeutic purposes.